A novel selective progesterone receptor modulator asoprisnil (J867) inhibits proliferation and induces apoptosis in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells

Journal of Clinical Endocrinology and Metabolism

Volumn 91, Issue 4, 2006, Pages 1296-1304

  Chen, Wei ^a   Ohara, Noriyuki ^a   Wang, Jiayin ^a   Xu, Qin ^a   Liu, Jin ^a   Morikawa, Akira ^a   Sasaki, Hiroko ^a   Yoshida, Shigeki ^a   Demanno, Deborah A ^b   Chwalisz, Kristof ^b   Maruo, Takeshi ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TAP PHARMACEUTICAL PRODUCTS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASOPRISNIL; CASPASE 3; CYCLINE; PROTEIN BCL 2; CASP3 PROTEIN, HUMAN; CASPASE; ESTRANE DERIVATIVE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OXIME; PROGESTERONE RECEPTOR;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; DRUG EFFECT; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; MYOMETRIUM; NICK END LABELING; PRIORITY JOURNAL; PROTEIN EXPRESSION; UTERUS MYOMA; WESTERN BLOTTING; CELL CULTURE; DOSE RESPONSE; FEMALE; GENETICS; LEIOMYOMA; METABOLISM; PATHOLOGY; PROTO ONCOGENE; UTERUS CANCER;

APOPTOSIS; BLOTTING, WESTERN; CASPASE 3; CASPASES; CELL PROLIFERATION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRENES; FEMALE; GENES, BCL-2; HUMANS; IN SITU NICK-END LABELING; LEIOMYOMA; MYOMETRIUM; OXIMES; POLY(ADP-RIBOSE) POLYMERASES; PROLIFERATING CELL NUCLEAR ANTIGEN; RECEPTORS, PROGESTERONE; UTERINE NEOPLASMS;

EID: 33646067165     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2005-2379     Document Type: Article

References (36)

1. Maruo T, Ohara N, Wang J, Matsuo H 2004 Sex steroidal regulation of uterine leiomyoma growth and apoptosis. Hum Reprod Update 10:207-220
2. Leonhardt SA, Edwards DP 2002 Mechanism of action of progesterone antagonists. Exp Biol Med 227:969-980
3. Kastner P, Krust A, Turcotte B, Stropp U, Tora L, Gronemeyer H, Chambon P 1990 Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J 9:1603-1614
4. Vegeto E, Shahbaz MM, Wen DX, Goldman ME, O'Malley BW, McDonnell DP 1993 Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function. Mol Endocrinol 7:1244-1255
5. Wen DX, Xu Y-F, Mais DE, Goldman ME, McDonnell DP 1994 The A and B isoforms of the human progesterone receptor operate through distinct signaling pathways within target cells. Mol Cell Biol 14:8356-8364
6. Brandon DD, Bethea CL, Strawn EY, Novy MJ, Burry KA, Harrington MS, Erickson TE, Warner C, Keenan EJ, Clinton GM 1993 Progesterone receptor messenger ribonucleic acid and protein are overexpressed in human uterine leiomyomas. Am J Obstet Gynecol 169:78-85
7. Viville B, Charnock-Jones DS, Sharkey AM, Wetzka B, Smith SK 1997 Distribution of the A and B forms of the progesterone receptor messenger ribonucleic acid and protein in uterine leiomyomata and adjacent myometrium. Hum Reprod 12:815-822
8. Nisolle M, Gillerot S, Casanas-Roux F, Squifflet J, Berliere M, Donnez J 1999 Immunohistochemical study of the proliferation index, oestrogen receptors and progesterone receptors A and B in leiomyomata and normal myometrium during the menstrual cycle and under gonadotropin-releasing hormone agonist therapy. Hum Reprod 14:2844-2850
9. Tiltman AJ 1985 The effect of progestins on the mitotic activity of uterine fibromyomas. Int J Gynecol Pathol 4:89-96
10. Carr BR, Marshburn PB, Weatherall PT, Bradshaw KD, Breslau NA, Byrd W, Roark M, Steinkampf MP 1993 An evaluation of the effect of gonadotropin- releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: a prospective, randomized, double blind, placebo-controlled, crossover trial. J Clin Endocrinol Metab 76:1217-1223
11. Friedman AJ, Daly M, Juneau-Norcross M, Rein MS, Fine C, Gleason R, Leboff M 1993 A prospective, randomized trial of gonadotropin-releasing hormone agonist plus estrogen-progestin or progestin "add-back" regimens for women with leiomyomata uteri. J Clin Endocrinol Metab 76:1439-1445
12. Kettel LM, Murphy AA, Morales AJ, Yen SSC 1994 Clinical efficacy of the antiprogesterone RU486 in the treatment of endometriosis and uterine fibroids. Hum Reprod 9(Suppl 1):116-120
13. Murphy AA, Morales AJ, Kettel LM, Yen SSC 1995 Regression of uterine leiomyomata to the antiprogesterone RU486: dose-response effect. Fertil Steril 64:187-190
14. Eisinger SH, Meldrum S, Fiscella K, Le Roux HD, Guzick DS 2003 Low-dose mifepristone for uterine leiomyomata. Obstet Gynecol 101:243-250
15. Chwalisz K, Perez MC, DeManno D, Winkel C, Schubert G, Elger W 2005 Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocr Rev [Erratum (2005) 26:703] 26:423-438
16. DeManno D, Elger W, Garg R, Lee R, Schneider B, Hess-Stumpp H, Schubert G, Chwalisz K 2003 Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy. Steroids 68:1019-1032
17. Schubert G, Elger W, Kaufmann G, Schneider B, Reddersen G, Chwalisz K 2005 Discovery, chemistry, and reproductive pharmacology of asoprisnil and related 11β-benzaldoxime substituted selective progesterone receptor modulators (SPRMs). Semin Reprod Med 23:58-73
18. Chwalisz K, Elger W, Stickler T, Mattia-Goldberg C, Larsen L 2005 The effects of 1-month administration of asoprisnil (J867), a selective progesterone receptor modulator, in healthy premenopausal women. Hum Reprod 20:1090-1099
19. Chwalisz K, Parker RL, Williamson S, Larsen L, McCrary K, Elger W 2003 Treatment of uterine leiomyomas with the novel selective progesterone receptor modulator (SPRM) J867. J Soc Gynecol Invest 10(Suppl):301A (Abstract)
20. Chwalisz K, Larsen L, McCrary K, Edmonds A 2004 Effects of the novel selective progesterone receptor modulator (SPRM) asoprisnil on bleeding patterns in subjects with leiomyomata. J Soc Gynecol Invest 11(Suppl):320A-321A (Abstract)
21. Chwalisz K, Mattia-Goldberg K, Lee M, Elger W, Edmonds A 2004 Treatment of endometriosis with the novel selective progesterone receptor modulator (SPRM) asoprisnil. Fertil Steril 82:S83 (Abstract O-207)
22. Xu Q, Takekida S, Ohara N, Chen W, Sitruk-Ware R, Johansson EDB, Maruo T 2005 Progesterone receptor modulator CDB-2914 down-regulates proliferative cell nuclear antigen and Bcl-2 protein expression and up-regulates caspase-3 and poly(adenosine 5′-diphosphate-ribose) polymerase expression in cultured human uterine leiomyoma cells. J Clin Endocrinol Metab 90:953-961
23. Matsuo H, Maruo T, Samoto T 1997 Increased expression of Bcl-2 protein in human uterine leiomyoma and its up-regulation by progesterone. J Clin Endocrinol Metab 82:293-299
24. Berridge MV, Tan AS 1993 Characterization of the cellular reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT): subcellular localization, substrate dependence, and involvement of mitochondrial electron transport in MTT reduction. Arch Biochem Biophys 303:474-482
25. Bradford MM 1976 A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254
26. Shimomura Y, Matsuo H, Samoto T, Maruo T 1998 Up-regulation by progesterone of proliferating cell nuclear antigen and epidermal growth factor expression in human uterine leiomyoma. J Clin Endocrinol Metab 83:2192-2198
27. Musgrove EA, Lee CSL, Cornish AL, Swarbrick A, Sutherland RL 1997 Antiprogestin inhibition of cell cycle progression in T-47D breast cancer cells is accompanied by induction of the cyclin-dependent kinase inhibitor p21. Mol Endocrinol 11:54-66
28. Gaddy VT, Barrett JT, Delk JN, Kallab AM, Porter AG, Schoenlein PV 2004 Mifepristone induces growth arrest, caspase activation, and apoptosis of estrogen receptor-expressing, antiestrogen-resistant breast cancer cells. Clin Cancer Res 10:5215-5225
29. Riedl SJ, Shi Y 2004 Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol 5:897-907
30. Shiozaki EN, Shi Y 2004 Caspases, IAPs and Smac/DIABLO: mechanisms from structural biology. Trends Biochem Sci 39:486-494
31. Shi Y 2004 Caspase activation, inhibition, and reactivation: a mechanistic view. Protein Sci 13:1979-1987
32. Cohen GM 1997 Caspases: the executioners of apoptosis. Biochem J 326:1-16
33. Bouchard VJ, Rouleau M, Poirier GG 2003 PARP-1, a determinant of cell survival in response to DNA damage. Exp Hematol 31:446-454
34. Pieper AA, Verma A, Zhang J, Snyder SH 1999 Poly(ADP-ribose) polymerase, nitric oxide and cell death. Trends Pharmacol Sci 20:171-181
35. Reed JC, Jurgensmeier JM, Matsuyama S 1998 Bcl-2 family proteins and mitochondria. Biochim Biophys Acta 1366:127-137
36. Pieber D, Allport VC, Hills F, Johnson M, Bennett PR 2001 Interactions between progesterone receptor isoforms in myometrial cells in human labour. Mol Hum Reprod 7:875-879